MDH Looking into LeafLine Lab Prescription Delays

December 03, 2017 07:43 AM

A spokesperson for the Minnesota Department of Health said regulators are "looking into the matter" after LeafLine Labs shut down its Eagan location and was late in filling medical marijuana prescriptions.

MDH spokesperson Scott Smith said the department cannot comment on specifics regarding any investigation until it is finished and issued an email response to KSTP inquiries about the prescription delays at LeafLine Labs

Advertisement

"The Minnesota Department of Health is aware of recent reports related to operations issues at one of the state's medical cannabis manufacturers. While we don't have any additional information available at this point, we are looking into the matter and will provide more details when we are able to do so," he said.

LeafLine Labs issued an apology to its clients Tuesday that said, in part, "LeafLine has plenty of inventory, but due to some unforeseen delays at the lab, including the recent holiday, we are still waiting for our certificate of analysis to release more product to our patients."

RELATED: Some Medical Marijuana Patients Scramble to Get Prescriptions

LeafLine Labs blamed the delays on an independent third-party laboratory that is required by the state to test the medical marijuana products and certify them before they can be sold.

Kellie Casey said she is a LeafLine Labs client and had to wait several days to refill her prescription. She now intends to file a complaint with the Minnesota Health Department.

"This was a tough ride, a really tough ride for a lot of us," she sadi. "And I think it is important to say something when things go wrong, because this should not have happened."

The Minnesota Health Department issued a news release announcing it had renewed LifeLine's registration with the state as a medical cannabis provider for the next two years, but followed that up with a strong statement about enforcement in the future.

"While we cannot offer specific comment during any active investigation, it is important for patients and the public to know that the new manufacturer agreements incorporate stricter regulatory enforcement authorities provided by the 2017 Minnesota Legislature, including the power to suspend manufacturers for up to 90 days for violations of state law or rules. We will use these new authorities, as circumstances warrant, to ensure we continue to operate a program that works effectively for Minnesota's patients," the statement read.

LeafLine Labs issued a statement Saturday in response to the statement from MDH,  "Any patient complaint receives a thorough investigation from the Minnesota Department of Health, as we collaboratively work to make our state's medical cannabis program the nation's gold standard. We have already spoken to MDH about the recent third party lab delays and its impact on our clinic schedule, and have maintained our focus on our patients throughout."

 

Credits

Jay Kolls

Copyright 2017 - KSTP-TV, LLC A Hubbard Broadcasting Company

Advertisement

Minnesota Senate Appointment Could Spur Legal Fight

Dayton Selects Smith to Fill Franken's Senate Seat

Minneapolis Weighs a Shorter School Year

Minnesota's Next Senator: Quiet Organizer, Late to Politics

Fischbach Expects to Retain Senate Seat Upon Becoming Lt. Governor

6 Days after Surgery, KSTP Anchor Chris Egert Takes on Physical Therapy

Advertisement